Literature DB >> 17502475

Linezolid-induced posterior reversible leukoencephalopathy syndrome.

Simon Nagel1, Martin Köhrmann, Hagen B Huttner, Brigitte Storch-Hagenlocher, Stefan Schwab.   

Abstract

OBJECTIVE: To describe a 71-year-old woman who developed clinical and neuroradiological features of posterior reversible leukoencephalopathy syndrome with a compromised blood-brain barrier after 5 days of intravenous linezolid therapy for an infected hip prosthesis.
DESIGN: Case report.
SETTING: Academic research. MAIN OUTCOME MEASURES: Posterior reversible leukoencephalopathy syndrome was documented using serial cranial magnetic resonance imaging, and the blood-brain barrier disturbance was demonstrated by contrast enhancement of a lesion and by cerebrospinal fluid analysis.
RESULTS: Other causes of posterior reversible leukoencephalopathy syndrome, such as renal failure, severe hypertension, inflammatory syndromes, and infectious diseases of the central nervous system, were excluded during hospitalization. After discontinuation of linezolid therapy, the patient's condition improved rapidly.
CONCLUSION: To our knowledge, this is the first report of likely linezolid-induced posterior reversible leukoencephalopathy syndrome with an altered blood-brain barrier after short-term intravenous therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17502475     DOI: 10.1001/archneur.64.5.746

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  9 in total

Review 1.  [Headache and hypertension. Myth and evidence].

Authors:  T Liman; E Siebert; M Endres
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

2.  Early onset probable linezolid-induced encephalopathy.

Authors:  Jeffery Fletcher; Laura E Aykroyd; Eric C Feucht; James M Curtis
Journal:  J Neurol       Date:  2009-11-05       Impact factor: 4.849

3.  Lysergic acid amide-induced posterior reversible encephalopathy syndrome with status epilepticus.

Authors:  Stephane Legriel; Fabrice Bruneel; Odile Spreux-Varoquaux; Aurelie Birenbaum; Marie Laure Chadenat; François Mignon; Nathalie Abbosh; Matthieu Henry-Lagarrigue; Laure Revault D'Allonnes; Pierre Guezennec; Gilles Troche; Jean Pierre Bedos
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

4.  Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis.

Authors:  Patrick A Thompson; Carl E Allen; Terzah Horton; Jeremy Y Jones; Alexander A Vinks; Kenneth L McClain
Journal:  Pediatr Blood Cancer       Date:  2009-05       Impact factor: 3.167

5.  Tacrolimus associated posterior reversible encephalopathy syndrome - a case series and review.

Authors:  Susmitha Apuri; Kristin Carlin; Edward Bass; Phuong Thuy Nguyen; John N Greene
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-02-18       Impact factor: 2.576

6.  An unusual case of posterior reversible encephalopathy syndrome in a patient being weaned from intrathecal morphine.

Authors:  Jasper Van Aalst; Onno P Teernstra; Wim E Weber; Kim Rijkers
Journal:  Int Med Case Rep J       Date:  2016-05-17

7.  Linezolid Toxicity and Mitochondrial Susceptibility: A Novel Neurological Complication in a Lebanese Patient.

Authors:  Ossama K Abou Hassan; Mohamad Karnib; Riyad El-Khoury; Georges Nemer; Mamdouha Ahdab-Barmada; Pierre BouKhalil
Journal:  Front Pharmacol       Date:  2016-09-20       Impact factor: 5.810

8.  Daptomycin-Induced Posterior Reversible Encephalopathy Syndrome (PRES).

Authors:  A Bitar De Zayas-Enriquez; C Soper
Journal:  Case Rep Neurol Med       Date:  2019-02-24

9.  Delayed Posterior Reversible Leukoencephalopathy Syndrome Triggered by FLOT Chemotherapy.

Authors:  Jordi Gandini; Mario Manto; Nicolas Charette
Journal:  Front Neurol       Date:  2020-01-30       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.